168 related articles for article (PubMed ID: 32481351)
21. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
23. IgA nephropathy after pembrolizumab therapy for mesothelioma.
Wang R; Das T; Takou A
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257374
[TBL] [Abstract][Full Text] [Related]
24. IgA nephropathy in a patient with dominant dystrophic epidermolysis bullosa.
Kawasaki Y; Isome M; Takano K; Suyama K; Imaizumi T; Matsuura H; Ichii K; Hashimoto K; Hosoya M
Tohoku J Exp Med; 2008 Apr; 214(4):297-301. PubMed ID: 18441504
[TBL] [Abstract][Full Text] [Related]
25. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
26. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger A; La Rosa S; Zurcher JP; Zimmermann S; Spertini F; Coukos G; Obeid M
J Immunother Cancer; 2018 Dec; 6(1):156. PubMed ID: 30587227
[TBL] [Abstract][Full Text] [Related]
27. [A Case of Delayed-Onset Acute Interstitial Nephritis following Nivolumab Treatment in a Patient with Advanced Esophagogastric Junction Cancer].
Ozawa T; Shoda K; Kawaguchi Y; Akaike H; Maruyama S; Takiguchi K; Shiraishi K; Furuya S; Saito R; Nakata Y; Amemiya H; Kawaida H; Ashizawa N; Nakayama Y; Ichikawa D
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1633-1635. PubMed ID: 38303365
[TBL] [Abstract][Full Text] [Related]
28. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
Abe K; Ishikawa Y; Fujiwara M; Yukawa H; Yanagihara T; Takei S; Arioka H; Kita Y
Medicine (Baltimore); 2022 Jan; 101(2):e28428. PubMed ID: 35029182
[TBL] [Abstract][Full Text] [Related]
30. DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer.
Sunakawa Y; Inoue E; Matoba R; Kawakami H; Sato Y; Nakajima TE; Muro K; Ichikawa W; Fujii M
Future Oncol; 2019 Jul; 15(21):2441-2447. PubMed ID: 31140303
[No Abstract] [Full Text] [Related]
31. Linear IgA Disease of the Gingiva Following Nivolumab Therapy.
Jonna S; Neiders M; Lakshmanan S; Khan A; DeKlotz T; Lanasa D; Gibney GT; Liu SV
J Immunother; 2019; 42(9):345-347. PubMed ID: 31246639
[TBL] [Abstract][Full Text] [Related]
32. Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis.
Kashiwada T; Minegishi Y; Saito Y; Kato T; Atsumi K; Seike M; Kubota K; Terasaki Y; Gemma A
J Nippon Med Sch; 2019; 86(1):43-47. PubMed ID: 30918156
[TBL] [Abstract][Full Text] [Related]
33. Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report.
Hu Q; Hasuda H; Ueki K; Tsuchimoto A; Zaitsu Y; Tsuda Y; Hisamatsu Y; Nakashima Y; Ando K; Kimura Y; Oki E; Mori M
Int Cancer Conf J; 2020 Jul; 9(3):127-132. PubMed ID: 32582516
[TBL] [Abstract][Full Text] [Related]
34. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.
Sawada A; Kawanishi K; Horita S; Koike J; Honda K; Ochi A; Komoda M; Tanaka Y; Unagami K; Okumi M; Shimizu T; Ishida H; Tanabe K; Nagashima Y; Nitta K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():48-52. PubMed ID: 26971743
[TBL] [Abstract][Full Text] [Related]
35. [MCNS, which secondary developed into incidental IgA nephropathy--a case report].
Tsunehisa N; Takemura T; Inui T; Kamiya H
Nihon Jinzo Gakkai Shi; 1992 Oct; 34(10):1095-9. PubMed ID: 1289609
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin A nephropathy complicating pulmonary tuberculosis.
De Siati L; Paroli M; Ferri C; Muda AO; Bruno G; Barnaba V
Ann Diagn Pathol; 1999 Oct; 3(5):300-3. PubMed ID: 10556477
[TBL] [Abstract][Full Text] [Related]
37. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
[TBL] [Abstract][Full Text] [Related]
38. Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review.
Fernandes PF; Júnior GB; Barros FA; Sousa DC; Franco LM; Patrocínio RM
Invest Clin; 2006 Dec; 47(4):405-11. PubMed ID: 17176908
[TBL] [Abstract][Full Text] [Related]
39. [Clinical Evaluation of the Efficacy and Adverse Effects of Nivolumab Treatment for Patients with Advanced Gastric Cancer].
Ohta A; Komatsu S; Tsuji R; Tanaka S; Kumano T; Imura K; Shimomura K; Ikeda J; Taniguchi F; Doi T; Yamada S; Tomatsuri N; Yoshida N; Shioaki Y
Gan To Kagaku Ryoho; 2020 Apr; 47(4):725-727. PubMed ID: 32389997
[TBL] [Abstract][Full Text] [Related]
40. [A case of IgA nephropathy associated with silicosis].
Fujii Y; Arimura Y; Waku M; Fujii A; Nakabayashi K; Nagasawa T
Nihon Jinzo Gakkai Shi; 2001 Oct; 43(7):613-8. PubMed ID: 11725560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
